November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 16th, 2026FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast CancerThe FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.Read more
November 15th, 2026Five Under 5: Top Oncology Videos for the Week of 11/8The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.Read more
November 14th, 2026The OncFive: Top Oncology Articles for the Week of 11/8The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.Read more
November 13th, 2026OncLive Weekly News Quiz (11/13/2026): Did You Miss Crucial TGCT, Breast Cancer, Bladder Cancer, and Lymphoma Updates?Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.Read more
November 11th, 2026Breast Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.Read more
November 9th, 2026Gedatolisib sNDA Accepted by FDA for PIK3CA-Mutated, HR+, HER2– Advanced Breast CancerThe FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.Read more
November 9th, 2026Breast Cancer’s Fastest-Moving Questions: Which Expert Recommendations Have Held Up?Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.Read more